Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 913-923

  Srinivasan, Venkatramanujan ^a   Brzezinski, Amnon ^b   Pandi Perumal, Seithikurippu R ^c   Spence, D Warren ^d   Cardinali, Daniel P ^e,f   Brown, Gregory M ^g,h  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Somnogen Inc   (United States)

^d Canadian Sleep Institute   (Canada)

^e PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Agomelatine; Benzodiazepines; Insomnia; Melatonin; Ramelteon

Indexed keywords

AGOMELATINE; AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; BETA METHYL 6 CHLOROMELATONIN; ESZOPICLONE; FLUCONAZOLE; FLUOXETINE; HORMONE RECEPTOR STIMULATING AGENT; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; LY 156735; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN AGONIST; MELATONIN DERIVATIVE; PAROXETINE; PLACEBO; PROLACTIN; RAMELTEON; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TASIMELTEON; UNCLASSIFIED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADRENAL FUNCTION; ALERTNESS; AMINOTRANSFERASE BLOOD LEVEL; ANTEROGRADE AMNESIA; ANTICHOLINERGIC SYNDROME; BINDING AFFINITY; BRADYCARDIA; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DIZZINESS; DRIVING ABILITY; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HANGOVER; HORMONE BLOOD LEVEL; HUMAN; HYPOTENSION; HYPOTHERMIA; INSOMNIA; MAJOR DEPRESSION; MEMORY DISORDER; MENSTRUAL CYCLE; MORNING DOSAGE; NAUSEA; NONHUMAN; OVULATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POLYSOMNOGRAPHY; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR DISORDER; REPRODUCTION; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS HEADACHE; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; SLEEP WAKING CYCLE; SOMNOLENCE; SORE THROAT; SPINAL CORD INJURY; THYROID FUNCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ACETAMIDES; ANIMALS; BENZODIAZEPINES; BENZOFURANS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DEPRESSIVE DISORDER; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; INDOLES; MELATONIN; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 79955993458     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.013     Document Type: Review

References (181)

1. Allen D., Curran H.V., Lader M. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993, 45:313-320.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Press, Washington, D.C. 4th ed. (DSM-IV-TR).
3. Ancoli-Israel S., Walsh J.K., Mangano R.M., Fujimoro M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. J Clin Psychiatry 1999, 1:114-120.
4. Ancoli-Israel S., Richardson G.S., Mangano R.M., Jenkins L., Hall P., Jones W.S. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005, 6:107-113.
5. Arendt J., Skene D.J. Melatonin as a chronobiotic. Sleep Med Rev 2005, 9:25-39.
6. Arendt J., Borbely A.A., Franey C., Wright J. The effect of chronic small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett 1984, 45:317-321.
7. Arendt J., Bojkowski C., Folkard S., Franey C., Marks V., Minors D., et al. Some effects of melatonin and the control of its secretion in humans. Photoperiodism, melatonin and the pineal 1985, 266-283. S.Pitman, London. D. Evered, S. Clark (Eds.).
8. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl 2007, 104-115.
9. Ayadi N., Neifar S., Maalej M. Amnesic and criminal effect of benzodiazepines: case report with lorazepam. [French]. Therapie 1998, 53:596-598.
10. Bellipanni G., Di Marzo F., Blasi F., Di Marzo A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann NY Acad Sci 2005, 1057:393-402.
11. Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial?. J Psychiatr Pract 2006, 12:229-243.
12. Blaschke G., Hempel G., Muller W.E. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 1993, 5:419-421.
13. Brown G.M., Young S.N., Gauthier S., Tsui H., Grota L.J. Melatonin in human cerebrospinal fluid in daytime; its origin and variation with age. Life Sci 1979, 25:929-936.
14. Brunner P., Sozer-Topcular N., Jockers R., Ravid R., Angeloni D., Fraschini F., et al. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 2006, 50:311-316.
15. Brzezinski A., Vangel M.G., Wurtman R.J., Norrie G., Zhdanova I., Ben-Shushan A., et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005, 9:41-50.
16. Buscemi N., Vandermeer B., Pandya R., Hooton N., Tjosvold L., Hartling L., et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ) 2004, 1-7.
17. Buysse D.J. Diagnosis and assessment of sleep and circadian rhythm disorders. J Psychiatr Pract 2005, 11:102-115.
18. Carlson J.N., Haskew R., Wacker J., Maisonneuve I.M., Glick S.D., Jerussi T.P. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 2001, 415:181-189.
19. Carman J.S., Post R.M., Buswell R., Goodwin F.K. Negative effects of melatonin on depression. Am J Psychiatry 1976, 133:1181-1186.
20. Celada P., Puig M., Amargos-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004, 29:252-265.
21. Claustrat B., Brun J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005, 9:11-24.
22. Cricco M., Simonsick E.M., Foley D.J. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001, 49:1185-1189.
23. Crowley S.J., Lee C., Tseng C.Y., Fogg L.F., Eastman C.I. Combinations of bright light, scheduled dark, sunglasses, and melatonin to facilitate circadian entrainment to night shift work. J Biol Rhythms 2003, 18:513-523.
24. Czeisler C.A., Weitzman E.D., Moore-Ede M.C., Zimmerman J.C., Knauer R.S. Human sleep: Its duration and organization depend on its circadian phase. Science 1980, 210:1264-1267.
25. Daan S., Beersma D.G., Borbely A.A. Timing of human sleep: recovery process gated by a circadian pacemaker. Am J Physiol 1984, 246:R161-R183.
26. den Boer J.A., Bosker F.J., Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 2006, 21(Suppl. 1):S21-S24.
27. Dijk D.J., Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 1997, 12:627-635.
28. Dijk D.J., Czeisler C.A. Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett 1994, 166:63-68.
29. Dobkin R.D., Menza M., Bienfait K.L., Allen L.A., Marin H., Gara M.A. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int 2009, 15:13-18.
30. Dollins N., Lynch H.J., Wurtman R.J., Deng M.H., Kischka K.U., Gleason R.E., et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology 1993, 112:490-496.
31. Dollins N., Zhdanova I.V., Wurtman R.J., Lynch H.J., Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994, 91:1824-1828.
32. Drake C.L., Roehrs T., Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003, 18:163-176.
33. Drover D., Lemmens H., Naidu S., Cevallos W., Darwish M., Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000, 22:1443-1461.
34. Dubocovich M.L., Cardinali D.P., Delagrange P., Krause D.N., Strosberg D., Sugden D., et al. Melatonin receptors. The IUPHAR Compendium of Receptor Characterization and Classification 2000, 271-277. IUPHAR Media, London. IUPHAR (Ed.).
35. Egger S.S., Bachmann A., Hubmann N., Schlienger R.G., Krahenbuhl S. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging 2006, 23:823-837.
36. Elie R., Ruther E., Farr I., Emilien G., Salinas E. Sleep latency is shortened during 4weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999, 60:536-544.
37. Erman M., Seiden D., Zammit G., Sainati S., Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006, 7:17-24.
38. Fee D.B., Swartz K.R., Scheff N., Roberts K., Gabbita P., Scheff S. Melatonin-analog, beta-methyl-6-chloromelatonin, supplementation in spinal cord injury. Brain Res 2010, 1340:81-85.
39. Fisher S.P., Sugden D. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neurosci Lett 2009, 457:93-96.
40. Fisher S.P., Davidson K., Kulla A., Sugden D. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat. J Pineal Res 2008, 45:125-132.
41. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989, 262:1479-1484.
42. Fourtillan J.B., Brisson A.M., Fourtillan M., Ingrand I., Decourt J.P., Girault J. Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol Endocrinol Metab 2001, 280:E11-E22.
43. Fry J., Scharf M., Mangano R., Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000, 15:141-152.
44. Fuller P.M., Gooley J.J., Saper C.B. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms 2006, 21:482-493.
45. Garfinkel D., Laudon M., Nof D., Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995, 346:541-544.
46. Gehrman P.R., Connor D.J., Martin J.L., Shochat T., Corey-Bloom J., Ancoli-Israel S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with alzheimer disease. Am J Geriatr Psychiatry 2009, 17:166-169.
47. Gilbert S.S., van den Heuvel C.J., Kennaway D.J., Dawson D. Peripheral heat loss: a predictor of the hypothermic response to melatonin administration in young and older women. Physiol Behav 1999, 66:365-370.
48. Giles D.E., Jarrett R.B., Roffwarg H.P., Rush A.J. Reduced rapid eye movement latency. A predictor of recurrence in depression. Neuropsychopharmacology 1987, 1:33-39.
49. Golombek D.A., Pevet P., Cardinali D.P. Melatonin effects on behavior: possible mediation by the central GN2Aergic system. [Review] [175 refs]. Neurosci Biobehav Rev 1996, 20:403-412.
50. Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol 2005, 15:S419.
51. Haimov I., Laudon M., Zisapel N., Souroujon M., Nof D., Shlitner A., et al. Sleep disorders and melatonin rhythms in elderly people. Br Med J 1994, 309:167.
52. Hair P.I., McCormack P.L., Curran M.P. Eszopiclone: a review of its use in the treatment of insomnia. Drugs 2008, 68:1415-1434.
53. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
54. Hedner J., Yacche R., Emilien G., Farr I., Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000, 15:704-712.
55. Hughes R.J., Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997, 20:124-131.
56. Hunt A.E., Al-Ghoul W.M., Gillette M.U., Dubocovich M.L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 2001, 280:C110-C118.
57. Iguchi H., Kato K.-I., Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982, 55:27-29.
58. Irwin M., Clark C., Kennedy B., Christian G.J., Ziegler M. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun 2003, 17:365-372.
59. Johnson M.W., Suess P.E., Griffiths R.R. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006, 63:1149-1157.
60. Kamel N.S., Gammack J.K. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006, 119:463-469.
61. Karim A., Tolbert D., Cao C., Zhao Z., Sainati S.M. Effects of fluconazole and ketoconazole on the pharmacodynamics of ramelteon (TAK-375) in normal healthy male and female subjects. Sleep 2004, 27:A53-A54. Suppl.
62. Karim A., Tolbert D., Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006, 46:140-148.
63. Kasper S., Hajak G., Wulff K., Hoogendijk W.J., Montejo A.L., Smeraldi E., et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010, 71:109-120.
64. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006, 16:93-100.
65. Kennedy S.H., Rizvi S.J. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010, 24:479-499.
66. Kitajima T., Kanbayashi T., Saitoh Y., Ogawa Y., Sugiyama T., Kaneko Y., et al. The effects of oral melatonin on the autonomic function in healthy subjects. Psychiatry Clin Neurosci 2001, 55:299-300.
67. Krystal A.D., Walsh J.K., Laska E., Caron J., Amato D.A., Wessel T.C., et al. Sustained efficacy of eszopiclone over 6months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26:793-799.
68. Kupfer D.J. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 2006, 16:S639-S643.
69. Lam R.W. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006, 21(Suppl. 1):S25-S29.
70. Leger D., Laudon M., Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004, 116:91-95.
71. Lemoine P., Nir T., Laudon M., Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55years and older and has no withdrawal effects. J Sleep Res 2007, 16:372-380.
72. Lerner A.B., Case J.D. Melatonin. Fed Proc 1960, 19:590-592.
73. Lerner A.B., Case J.D., Takahashi Y., Lee T.H., Mori N. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc 1958, 80:2587.
74. Lerner A.B., Case J.D., Heinzelman R.D. Structure of melatonin. J Am Chem 1959, 81:6084-6085.
75. Lewy A.J., Ahmed S., Jackson J.M., Sack R.L. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992, 9:380-392.
76. Lewy A.J., Bauer V.K., Ahmed S., Thomas K.H., Cutler N.L., Singer C.M., et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 1998, 15:71-83.
77. Lieberman H.R., Waldhauser F., Garfield G., Lynch H.J., Wurtman R.J. Effects of melatonin on human mood and performance. Brain Res 1984, 323:201-207.
78. Loo H., Hale A., D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002, 17:239-247.
79. Lopes M.C., Quera-Salva M.A., Guilleminault C. Cycling alternating pattern in the NREM sleep of patients within major depressive disorder: baseline results and change over time with a new antidepressant. Sleep Med 2005, 6(Suppl. 2):521-524.
80. Lopes M.C., Quera-Salva M.A., Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 2007, 9:33-41.
81. Lustberg L., Reynolds C.F. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000, 4:253-262.
82. MacFarlane J.G., Cleghorn J.M., Brown G.M., Streiner D.L. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991, 30:371-376.
83. Mayer G., Wang-Weigand S., Roth-Schechter B., Lehmann R., Staner C., Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009, 32:351-360.
84. Mazzucchelli C., Pannacci M., Nonno R., Lucini V., Fraschini F., Stankov B.M. The melatonin receptor in human brain: cloning experiments and distribution studies. Mol Brain Res 1996, 39:117-126.
85. McAllister-Williams R.H., Baldwin D.S., Haddad P.M., Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010, 25:95-102.
86. Middleton B., Arendt J., Stone B.M. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms 1997, 12:467-477.
87. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
88. Mini L., Wang-Weigand S., Zhang J. Ramelteon 8mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther 2008, 30:1316-1323.
89. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009, 15:32-51.
90. Molina S.M., Joshi K.G. A case of zaleplon-induced amnestic sleep-related eating disorder. J Clin Psychiatry 2010, 71:210-211.
91. Moltzen E.K., Bang-Andersen B. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century-a medicinal chemistry survey. Curr Top Med Chem 2006, 6:1801-1823.
92. Montgomery P., Dennis J. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med Rev 2004, 8:47-62.
93. Montgomery S.A., Kennedy S.H., Burrows G.D., Lejoyeux M., Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004, 19:271-280.
94. Monti J.M., Alvarino F., Cardinali D., Savio I., Pintos A. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 1999, 28:85-98.
95. Montplaisir J., Hawa R., Moller H., Morin C., Fortin M., Matte J., et al. Zopiclone and zaleplon vs. benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003, 18:29-38.
96. Morera A.L., Abreu-Gonzalez P., Henry M. Zaleplon increases nocturnal melatonin secretion in humans. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1013-1016.
97. Morin A.K. Strategies for treating chronic insomnia. Am J Manag Care 2006, 12:S230-S245.
98. Morin A.K., Willett K. The role of eszopiclone in the treatment of insomnia. Adv Ther 2009, 26:500-518.
99. Morin C.M., Hauri P.J., Espie C.A., Spielman A.J., Buysse D.J., Bootzin R.R. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999, 22:1134-1156.
100. Mulchahey J.J., Goldwater D.R., Zemlan F.P. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 2004, 75:1843-1856.
101. Nave R., Peled R., Lavie P. Melatonin improves evening napping. Eur J Pharmacol 1995, 275:213-216.
102. Nave R., Herer P., Haimov I., Shlitner A., Lavie P. Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil. Neurosci Lett 1996, 214:123-126.
103. Nickelsen T., Samel A., Vejvoda M., Wenzel J., Smith B., Gerzer R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 2002, 19:915-936.
104. Nordlund J.J., Lerner A.B. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab 1977, 45:768-774.
105. Norman T.R., Burrows G.D. Emerging treatments for major depression. Expert Rev Neurother 2007, 7:203-213.
106. Nowell P.D., Mazumdar S., Buysse D.J., Dew M.A., Reynolds C.F., Kupfer D.J. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997, 278:2170-2177.
107. Pandi-Perumal S.R., Srinivasan V., Poeggeler B., Hardeland R., Cardinali D.P. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007, 3:221-228.
108. Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Poeggeler B., Hardeland R., et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry 2008, 1-13.
109. Parrino L., Smerieri A., Giglia F., Milioli G., De P.F., Terzano M.G. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin Neuropharmacol 2008, 31:40-50.
110. Paul M.A., Gray G., Kenny G., Pigeau R.A. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003, 74:1263-1270.
111. Pires M.L., Benedito-Silva A.A., Pinto L., Souza L., Vismari L., Calil H.M. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res 2001, 31:326-332.
112. Quera Salva M.A., Vanier B., Laredo J., Hartley S., Chapotot F., Moulin C., et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007, 10:691-696.
113. Rajaratnam S.M., Polymeropoulos M.H., Fisher D.M., Roth T., Scott C., Birznieks G., et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet 2009, 373:482-491.
114. Ramakrishnan K., Scheid D.C. Treatment options for insomnia. Am Fam Physician 2007, 76:517-526.
115. Redman J., Armstrong S., Ng K.T. Free-running activity rhythms in the rat: entrainment by melatonin. Science 1983, 219:1089-1090.
116. Reid K., Van den Heuvel C., Dawson D. Day-time melatonin administration: effects on core temperature and sleep onset latency. J Sleep Res 1996, 5:150-154.
117. Richardson G., Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009, 24:103-111.
118. Richardson G.S., Zee P.C., Wang-Weigand S., Rodriguez L., Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med 2008, 4:456-461.
119. Richardson G.S., Zammit G., Wang-Weigand S., Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009, 70:467-476.
120. Riemann D., Berger M., Voderholzer U. Sleep and depression-results from psychobiological studies: an overview. Biol Psychol 2001, 57:67-103.
121. Rodenbeck A., Huether G., Ruther E., Hajak G. Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleep-wake rhythm disorders. J Pineal Res 1998, 25:201-210.
122. Rosenberg R.P. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006, 18:49-56.
123. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2006, 113:134-153.
124. Roth T., Stubbs C., Walsh J.K. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005, 28:303-307.
125. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006, 7:312-318.
126. Roth T., Seiden D., Wang-Weigand S., Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007, 23:1005-1014.
127. Roth T., Krystal A.D., Lieberman J.A. Long-term issues in the treatment of sleep disorders. CNS Spectr 2007, 12:1-14.
128. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006, 21(Suppl. 1):S31-S35.
129. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
130. Sack R.L., Hughes R.J., Edgar D.M., Lewy A.J. Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms?. Sleep 1997, 20:908-915.
131. Sanna E., Busonero F., Talani G., Carta M., Massa F., Peis M., et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002, 451:103-110.
132. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
133. Savaskan E., Olivieri G., Meier F., Brydon L., Jockers R., Ravid R., et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002, 32:59-62.
134. Savaskan E., Ayoub M.A., Ravid R., Angeloni D., Fraschini F., Meier F., et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005, 38:10-16.
135. Scheer F.A., Czeisler C.A. Melatonin, sleep, and circadian rhythms. Sleep Med Rev 2005, 9:5-9.
136. Shochat T., Luboshitzky R., Lavie P. Nocturnal melatonin onset is phase locked to the primary sleep gate. Am J Physiol 1997, 273:R364-R370.
137. Simmer E.D. A fugue-like state associated with diazepam use. Mil Med 1999, 164:442-443.
138. Sletten T., Burgess H., Savic N., Gilbert S., Dawson D. The effects of bright light and nighttime melatonin administration on cardiac activity. J Hum Ergol (Tokyo) 2001, 30:273-278.
139. Smith M.R., Lee C., Crowley S.J., Fogg L.F., Eastman C.I. Morning melatonin has limited benefit as a soporific for daytime sleep after night work. Chronobiol Int 2005, 22:873-888.
140. Srinivasan V., Pandi-Perumal S.R., Trahkt I., Spence D.W., Poeggeler B.H., Hardeland R., et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009, 119:821-846.
141. Stevenson S., Bryson S., Amayke D., Hibberd M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther 2004, 75:P22.
142. Stevenson S., Cornelisson K., Clarke E., Hibberd M. Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375). Clin Pharmacol Ther 2004, 75:P22.
143. Stoller M.K. Economic effects of insomnia. Clin Ther 1994, 16:873-897.
144. Summers M.O., Crisostomo M.I., Stepanski E.J. Recent developments in the classification, evaluation, and treatment of insomnia. Chest 2006, 130:276-286.
145. Thase M.E. Augmentation strategies for depression: history and concepts. CNS Spectr 2007, 12:3-5.
146. Thomson PDR Physician's desk reference. 2010 2010, Thomson PDR, Montvale, NJ. 64th ed.
147. Turek F.W., Gillette M.U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004, 5:523-532.
148. Tzischinsky O., Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep 1994, 17:638-645.
149. Uz T., Arslan A.D., Kurtuncu M., Imbesi M., Akhisaroglu M., Dwivedi Y., et al. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res 2005, 136:45-53.
150. Vachharajani N.N., Yeleswaram K., Boulton D.W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003, 92:760-772.
151. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004, 18:297-328.
152. Vgontzas A.N., Kales A. Sleep and its disorders. Annu Rev Med 1999, 50:387-400.
153. Victorri-Vigneau C., Dailly E., Veyrac G., Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007, 64:198-209.
154. Vollrath L., Semm P., Gammel G. Sleep induction by intranasal application of melatonin. Adv Biosci 1981, 29:327-329.
155. von Gall C., Stehle J.H., Weaver D.R. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002, 309:151-162.
156. Wade A.G., Ford I., Crawford G., McMahon A.D., Nir T., Laudon M., et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007, 23:2597-2605.
157. Waldhauser F., Lieberman H.R., Lynch H.J., Waldhauser M., Herkner K., Frisch H., et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 1987, 46:125-130.
158. Walsh J.K. Pharmacologic management of insomnia. J Clin Psychiatry 2004, 65(Suppl. 16):41-45.
159. Walsh J.K. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004, 65(Suppl. 8):13-19.
160. Walsh J.K., Roth T., Randazzo A., Erman M., Jamieson A., Scharf M., et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000, 23:1087-1096.
161. Walsh J.K., Vogel G.W., Scharf M., Erman M., William E.C., Schweitzer P.K., et al. A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Med 2000, 1:41-49.
162. Wan Q., Man H.Y., Liu F., Braunton J., Niznik H.B., Pang S.F., et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 1999, 2:401-403.
163. Weaver D.R., Reppert S.M. The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 1996, 8:109-112.
164. Weitzel K.W., Wickman J.M., Augustin S.G., Strom J.G. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther 2000, 22:1254-1267.
165. Winokur A., Gary K.A., Rodner S., Rae-Red C., Fernando A.T., Szuba M.P. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001, 14:19-28.
166. Wirz-Justice A., Werth E., Renz C., Muller S., Krauchi K. No evidence for a phase delay in human circadian rhythms after a single morning melatonin administration. J Pineal Res 2002, 32(1):1-5.
167. Wu Y.H., Swaab D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007, 8:623-636.
168. Wu Y.H., Fischer D.F., Kalsbeek A., Garidou-Boof M.L., van der Vliet J., van Heijningen C., et al. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock". FASEB J 2006, 20:1874-1876.
169. Wu Y.H., Zhou J.N., Balesar R., Unmehopa U., Bao A., Jockers R., et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol 2006, 499:897-910.
170. Wu Y.H., Zhou J.N., Van H.J., Jockers R., Swaab D.F. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2007, 28:1239-1247.
171. Wurtman R.J. Ramelteon: a melatonin receptor agonist. Sleep disorders: diagnosis and therapeutics 2008, 294-301. Informa Healthcare, London. S.R. Pandi-Perumal, J.C. Verster, J.M. Monti (Eds.).
172. Wyatt J.K., Dijk D.J., Ritz-de Cecco A., Ronda J.M., Czeisler C.A. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006, 29:609-618.
173. Zaidan R., Geoffriau M., Brun J., Taillard J., Bureau C., Chazot G., et al. Melatonin is able to influence its secretion in humans: description of a phase-response curve. Neuroendocrinology 1994, 60:105-112.
174. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009, 32:735-748.
175. Zammit G.K., McNabb L.J., Caron J., Amato D.A., Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004, 20:1979-1991.
176. Zammit G., Erman M., Wang-Weigand S., Sainati S., Zhang J., Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007, 3:495-504.
177. Zemlan F.P., Mulchahey J.J., Scharf M.B., Mayleben D.W., Rosenberg R., Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005, 66:384-390.
178. Zhdanova I.V. Melatonin as a hypnotic: pro. Sleep Med Rev 2005, 9:51-65.
179. Zhdanova I.V., Wurtman R.J., Lynch H.J., Ives J.R., Dollins N., Morabito C., et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995, 57:552-558.
180. Zhdanova I.V., Wurtman R.J., Morabito C., Piotrovska V.R., Lynch H.J. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996, 19:423-431.
181. Zupancic M., Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006, 20:981-992.